Literature DB >> 18242217

A molecular signature of gastric metaplasia arising in response to acute parietal cell loss.

Koji Nozaki1, Masako Ogawa, Janice A Williams, Bonnie J Lafleur, Vivian Ng, Ronny I Drapkin, Jason C Mills, Stephen F Konieczny, Sachiyo Nomura, James R Goldenring.   

Abstract

BACKGROUND & AIMS: Loss of gastric parietal cells is a critical precursor to gastric metaplasia and neoplasia. However, the origin of metaplasia remains obscure. Acute parietal cell loss in gastrin-deficient mice treated with DMP-777 leads to the rapid emergence of spasmolytic polypeptide/trefoil factor family 2 (TFF2)-expressing metaplasia (SPEM) from the bases of fundic glands. We now sought to characterize more definitively the pathway for emergence of SPEM.
METHODS: Emerging SPEM lineages in gastrin-deficient mice treated with DMP-777 were examined for immunolocalization of TFF2, intrinsic factor, and Mist1, and morphologically with electron microscopy. Emerging SPEM was isolated with laser-capture microdissection and RNA was analyzed using gene microarrays. Immunohistochemistry in mouse and human samples was used to confirm up-regulated transcripts.
RESULTS: DMP-777-induced SPEM was immunoreactive for TFF2 and the differentiated chief cell markers, Mist1 and intrinsic factor, suggesting that SPEM derived from transdifferentiation of chief cells. Microarray analysis of microdissected SPEM lineages induced by DMP-777 showed up-regulation of transcripts associated with G1/S cell-cycle transition including minichromosome maintenance deficient proteins, as well as a number of secreted factors, including human epididymis 4 (HE4). HE4, which was absent in the normal stomach, was expressed in SPEM of human and mouse and in intestinal metaplasia and gastric cancer in human beings.
CONCLUSIONS: Although traditionally metaplasia was thought to originate from normal mucosal progenitor cells, these studies indicate that SPEM evolves through either transdifferentiation of chief cells or activation of a basal cryptic progenitor. In addition, induction of metaplasia elicits the expression of secreted factors, such as HE4, relevant to gastric preneoplasia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18242217      PMCID: PMC2857727          DOI: 10.1053/j.gastro.2007.11.058

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

1.  Reversible drug-induced oxyntic atrophy in rats.

Authors:  J R Goldenring; G S Ray; R J Coffey; P C Meunier; P J Haley; T B Barnes; B D Car
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer.

Authors:  T C Wang; C A Dangler; D Chen; J R Goldenring; T Koh; R Raychowdhury; R J Coffey; S Ito; A Varro; G J Dockray; J G Fox
Journal:  Gastroenterology       Date:  2000-01       Impact factor: 22.682

3.  Dynamics of epithelial cells in the corpus of the mouse stomach. III. Inward migration of neck cells followed by progressive transformation into zymogenic cells.

Authors:  S M Karam; C P Leblond
Journal:  Anat Rec       Date:  1993-06

4.  Estimates of the world-wide prevalence of cancer for 25 sites in the adult population.

Authors:  Paola Pisani; Freddie Bray; D Maxwell Parkin
Journal:  Int J Cancer       Date:  2002-01-01       Impact factor: 7.396

5.  The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms.

Authors:  Lynne Bingle; Vanessa Singleton; Colin D Bingle
Journal:  Oncogene       Date:  2002-04-18       Impact factor: 9.867

6.  Aint/Tacc3 is highly expressed in proliferating mouse tissues during development, spermatogenesis, and oogenesis.

Authors:  Marjo Aitola; Christine M Sadek; Jan-Ake Gustafsson; Markku Pelto-Huikko
Journal:  J Histochem Cytochem       Date:  2003-04       Impact factor: 2.479

7.  Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma.

Authors:  J C Machado; P Pharoah; S Sousa; R Carvalho; C Oliveira; C Figueiredo; A Amorim; R Seruca; C Caldas; F Carneiro; M Sobrinho-Simões
Journal:  Gastroenterology       Date:  2001-10       Impact factor: 22.682

8.  Helicobacter pylori infection and the risk of gastric carcinoma.

Authors:  J Parsonnet; G D Friedman; D P Vandersteen; Y Chang; J H Vogelman; N Orentreich; R K Sibley
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

9.  Localization of transforming growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid secretion and mucosal renewal.

Authors:  R D Beauchamp; J A Barnard; C M McCutchen; J A Cherner; R J Coffey
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

10.  Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felis-infected mice.

Authors:  Sachiyo Nomura; Tammy Baxter; Hirokazu Yamaguchi; Charles Leys; Andrey B Vartapetian; James G Fox; Jeffrey R Lee; Timothy C Wang; James R Goldenring
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

View more
  92 in total

1.  Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer.

Authors:  James R Goldenring; Ki Taek Nam; Timothy C Wang; Jason C Mills; Nicholas A Wright
Journal:  Gastroenterology       Date:  2010-05-05       Impact factor: 22.682

Review 2.  Hedgehog signalling in gut development, physiology and cancer.

Authors:  Juanita L Merchant
Journal:  J Physiol       Date:  2011-12-05       Impact factor: 5.182

Review 3.  Oxyntic atrophy, metaplasia, and gastric cancer.

Authors:  James R Goldenring; Ki Taek Nam
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

4.  Heterogeneity in mouse spasmolytic polypeptide-expressing metaplasia lineages identifies markers of metaplastic progression.

Authors:  Victoria G Weis; Josane F Sousa; Bonnie J LaFleur; Ki Taek Nam; Jared A Weis; Paul E Finke; Nadia A Ameen; James G Fox; James R Goldenring
Journal:  Gut       Date:  2012-07-07       Impact factor: 23.059

5.  A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach.

Authors:  Christine P Petersen; Anne R Meyer; Carlo De Salvo; Eunyoung Choi; Cameron Schlegel; Alec Petersen; Amy C Engevik; Nripesh Prasad; Shawn E Levy; R Stokes Peebles; Theresa T Pizarro; James R Goldenring
Journal:  Gut       Date:  2017-02-14       Impact factor: 23.059

6.  Cell lineage dynamics in the process leading to intestinal metaplasia.

Authors:  Hirotsugu Sakamoto; Hiroyuki Mutoh; Hiroko Hayakawa; Miho Sashikawa; Kentaro Sugano
Journal:  J Gastroenterol       Date:  2011-03-08       Impact factor: 7.527

7.  The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation.

Authors:  Shradha S Khurana; Terrence E Riehl; Benjamin D Moore; Matteo Fassan; Massimo Rugge; Judith Romero-Gallo; Jennifer Noto; Richard M Peek; William F Stenson; Jason C Mills
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

8.  Loss of parietal cell expression of Sonic hedgehog induces hypergastrinemia and hyperproliferation of surface mucous cells.

Authors:  Chang Xiao; Sally A Ogle; Michael A Schumacher; Melissa A Orr-Asman; Marian L Miller; Nantaporn Lertkowit; Andrea Varro; Frederic Hollande; Yana Zavros
Journal:  Gastroenterology       Date:  2009-11-10       Impact factor: 22.682

9.  Loss of HGF activator inhibits foveolar hyperplasia induced by oxyntic atrophy without altering gastrin levels.

Authors:  Yukinori Yamagata; Susumu Aikou; Tsuyoshi Fukushima; Hiroaki Kataoka; Yasuyuki Seto; Hiroyasu Esumi; Michio Kaminishi; James R Goldenring; Sachiyo Nomura
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-10-11       Impact factor: 4.052

10.  Gastric carcinogenesis.

Authors:  Ismail Gomceli; Baris Demiriz; Mesut Tez
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.